These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11151429)

  • 21. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
    Hundt S; Haug U; Brenner H
    Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
    Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
    Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunochemical fecal occult blood test is inadequate for screening test of stomach cancer.
    Nakama H; Zhang B
    Dig Dis Sci; 2000 Nov; 45(11):2195-8. PubMed ID: 11215738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy?
    Endo H; Kato T; Sakai E; Taniguchi L; Arimoto J; Kawamura H; Higurashi T; Ohkubo H; Nonaka T; Taguri M; Inamori M; Yamanaka T; Sakaguchi T; Hata Y; Nagase H; Nakajima A
    J Gastroenterol; 2017 Feb; 52(2):194-202. PubMed ID: 27095444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of fecal occult blood and colorectal cancer].
    Herrerías Gutiérrez JM; Caunedo Alvarez JM; Herrerías Esteban JM
    Rev Esp Enferm Dig; 1999 May; 91(5):331-4. PubMed ID: 10362874
    [No Abstract]   [Full Text] [Related]  

  • 30. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
    Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Shiratori Y
    Gastroenterology; 2005 Aug; 129(2):422-8. PubMed ID: 16083699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic performance of fecal immunochemical test and sigmoidoscopy for advanced right-sided colorectal neoplasms.
    Castro I; Estevez P; Cubiella J; Hernandez V; González-Mao C; Rivera C; Iglesias F; Cid L; Soto S; de-Castro L; Vega P; Hermo JA; Macenlle R; Martínez A; Cid E; Gil I; Larzabal M; Bujanda L; Castells A;
    Dig Dis Sci; 2015 May; 60(5):1424-32. PubMed ID: 25407805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.
    Tam TK; Ng KK; Lau CM; Lai TC; Lai WY; Tsang LC
    Hong Kong Med J; 2011 Oct; 17(5):350-7. PubMed ID: 21979470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison between application of fecal occult blood quantitive testing instrument and colloidal gold strip method in colorectal cancer screening].
    Huang YQ; Zhang MW; Shen YZ; Ma HQ; Cai SR; Zhang SZ; Zheng S
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Aug; 47(8):747-51. PubMed ID: 24246083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal alpha 1-antitrypsin detection of colorectal neoplasia. An evaluation using HemoQuant.
    Moran A; Robinson M; Lawson N; Stanley J; Jones AF; Hardcastle JD
    Dig Dis Sci; 1995 Dec; 40(12):2522-5. PubMed ID: 8536506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
    Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
    Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.
    Levi Z; Birkenfeld S; Vilkin A; Bar-Chana M; Lifshitz I; Chared M; Maoz E; Niv Y
    Int J Cancer; 2011 May; 128(10):2415-24. PubMed ID: 20658527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer.
    Nakama H; Zhang B; Fattah AS
    Eur J Cancer; 2000 Mar; 36(5):647-50. PubMed ID: 10738130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.